Cystic echinococcosis (CE) is worldwide endemic parasitic zoonosis caused by tapeworm Echinococcus granulosus. In human, liver is most common organ affected up to 85%. Informal Working Group on Echinococcosis (IWGE) of World Health Organization (WHO) published a standard classification of the cysts based on ultrasound (1) and a consensus in 2010 suggesting treating with albendazol as first choice of treatment in uncomplicated CE1 and CE3a up to 5 cm (2). In the context of pandemic of COVID-19, patients who requires elective percutaneous or surgical treatment for symptomatic non-complicated hepatic CE must be delayed or suspended because this disease is not life threatening unless it's complicated and by the shortness of bed and the risk of intra-hospital COVID-19 infection. The aim of this case report is to describe the follow up of a patient with hepatic cystic echinococcosis who should have undergone elective precutaneous or surgical treatment, treated with albendazole in the context of a pandemic COVID-19.
Key words: Cystic echinococcosis, liver, albendazole, pandemic COVID-19
|
